A practical guide to deciding what evidence is needed before healthcare AI can be trusted, deployed and kept in use. It connects governance, data provenance, validation, clinical safety, regulation, human factors, monitoring and change control across the full AI lifecycle.
A model can be statistically strong and still be unsafe because the data is untraceable, the local population differs, the user cannot challenge it, the workflow has changed, the regulatory role is misunderstood or the supplier silently modifies the underlying model. Assurance therefore has to cover the complete socio-technical service from intended use to withdrawal.
Risk is shaped by intended purpose, autonomy, population, workflow and consequence. The same foundation model may be low-risk for brainstorming and high-consequence when embedded in patient-facing or clinical workflow.
An explanation of model behaviour is weak evidence if nobody can reconstruct what the inputs meant, where they came from or whether they were fit for the decision.
Dataset shift, workflow change and supplier updates can quietly move a deployed system outside the conditions that supported its original evidence.
The supplied Health Data Operability material provides the data-provenance, dataset-shift, computable-governance and trust foundations. Current authoritative sources cover ISO management and risk standards, the EU AI Act, NHS England clinical safety, MHRA/FDA/Health Canada medical-device AI, NICE evidence standards, NIST AI RMF and WHO guidance for AI and large multi-modal models.
Named owner, inventory, decision rights, risk acceptance, supplier accountability and governance integration.
Bounded purpose, users, population, autonomy, exclusions, regulatory classification and impact assessment.
Provenance, fitness, representativeness, labels, transformations, subgroup effects and historical context.
Independent testing, external/local validation, robustness, calibration, generative-AI factuality and uncertainty.
Hazards, workflow effects, automation bias, usability, professional challenge, fallback and escalation.
Medical-device status, AI-specific law, privacy, cybersecurity, confidentiality and procurement obligations.
Clinical effectiveness, value, limitations, provenance, user information and proportionate disclosure.
Drift, incidents, overrides, model/prompt changes, PCCPs where applicable, rollback and decommissioning.
No single framework is sufficient. ISO/IEC 42001 can organise an AI management system; ISO/IEC 23894 supports AI risk management; ISO/IEC 42005 addresses impacts; NIST AI RMF provides a voluntary risk-management structure. Health-specific deployments may additionally require medical-device conformity, clinical-safety standards, evidence frameworks and local data-protection duties.
The AI Act is generally applicable from 2 August 2026. Current amended dates place Annex III high-risk rules at 2 December 2027 and high-risk AI embedded in Annex I regulated products at 2 August 2028. Medical-device and other sectoral rules continue to matter independently.
AI with a medical purpose may fall under medical-device regulation. In England, DCB0129 and DCB0160 remain mandatory clinical-risk-management standards and are under formal review during 2026, not replaced.
FDA has final guidance on predetermined change control plans for AI-enabled device software. Health Canada published dedicated pre-market ML-enabled medical-device guidance in April 2026.
ISO/IEC 42001, ISO/IEC 23894, ISO/IEC 42005 and the NIST AI RMF provide complementary governance, risk, impact and assurance structures but do not establish clinical effectiveness by themselves.
| ID | Dimension | Finding | Evidence type | Severity | Confidence | Sources |
|---|
Record owner, supplier, intended purpose, risk tier, regulation, model/version dependency and lifecycle state.
Scale controls by autonomy and consequence, but retain basic accountability and source traceability even for assistive use.
Maintain approved evaluation methods, subgroup analysis, red-teaming, local validation and evidence templates.
Make dataset lineage, semantic context and fitness evidence part of the same assurance case as model metrics.
Track workflow outcomes, overrides, incidents, input drift, population change and supplier model updates.
Require model/configuration versioning, revalidation triggers, rollback and supplier exit before dependence becomes irreversible.
Regulatory classification is fact-specific and this resource is not legal or regulatory advice. Standards and AI regulation are changing quickly. In particular, the EU AI Act timeline was amended in July 2026, NHS England is reviewing DCB0129/DCB0160, NIST AI RMF 1.0 is being revised, and ISO/IEC 25059 has a second edition in final-draft development. Implementers should confirm the current rule or standard at the point of procurement, approval and deployment.
